BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 37064113)

  • 1. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective.
    Li Y; Xiang S; Pan W; Wang J; Zhan H; Liu S
    Front Oncol; 2023; 13():1166860. PubMed ID: 37064113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts.
    Perez-Penco M; Lara de la Torre L; Lecoq I; Martinenaite E; Andersen MH
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.
    Dong P; Yan Y; Fan Y; Wang H; Wu D; Yang L; Zhang J; Yin X; Lv Y; Zhang J; Hou Y; Liu F; Yu X
    Technol Cancer Res Treat; 2022; 21():15330338221142472. PubMed ID: 36573015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
    Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
    Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
    Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
    Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
    Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
    J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
    Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
    Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
    Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
    Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.
    Hu T; Shi R; Gu Y; Zhou H; Fang Y; Xu T; Xu Y; Wu X; Ma L; Shu Y
    Wiley Interdiscip Rev RNA; 2023 Oct; ():e1822. PubMed ID: 37817381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer.
    Vendramini-Costa DB; Francescone R; Franco-Barraza J; Luong T; Graves M; de Aquino AM; Steele N; Gardiner JC; Dos Santos SAA; Ogier C; Malloy E; Borghaei L; Martinez E; Zhigarev DI; Tan Y; Lee H; Zhou Y; Cai KQ; Klein-Szanto AJ; Wang H; Andrake M; Dunbrack RL; Campbell K; Cukierman E
    bioRxiv; 2024 May; ():. PubMed ID: 38798370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of the tumor microenvironment by curcumin.
    Fu X; He Y; Li M; Huang Z; Najafi M
    Biofactors; 2021 Nov; 47(6):914-932. PubMed ID: 34375483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.